{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:34:20Z","timestamp":1791815660547,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>It is believed that glycogen synthase kinase\u20103 hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) trial assessed the glycogen synthase kinase\u20103 inhibitor tideglusib as potential treatment. For the magnetic resonance imaging (MRI) substudy reported here, we assessed the progression of brain atrophy. TAUROS was a multinational, phase 2, double\u2010blind, placebo\u2010controlled trial in patients with mild\u2010to\u2010moderate PSP who were treated with oral tideglusib (600 mg or 800 mg daily) or with placebo for 1 year. A subset of patients underwent baseline and 52\u2010week MRI. Automated, observer\u2010independent, atlas\u2010based, and mask\u2010based volumetry was done on high\u2010resolution, T1\u2010weighted, three\u2010dimensional data. For primary outcomes, progression of atrophy was compared both globally (brain, cerebrum) and regionally (third ventricle, midbrain, pons) between the active and placebo groups (Bonferroni correction). For secondary outcomes, 15 additional brain structures were explored (Benjamini &amp; Yekutieli correction). In total, MRIs from 37 patient were studied (placebo group, N = 9; tideglusib 600 mg group, N = 19; tideglusib 800 mg group, N = 9). The groups compared well in their demographic characteristics. Clinical results showed no effect of tideglusib over placebo. Progression of atrophy was significantly lower in the active group than in the placebo group for the brain (mean \u00b1 standard error of the mean: \u22121.3% \u00b1 1.4% vs. \u22123.1% \u00b1 2.3%, respectively), cerebrum (\u22121.3% \u00b1 1.5% vs. \u22123.2% \u00b1 2.1%, respectively), parietal lobe (\u22121.6% \u00b1 1.9% vs. \u22124.1% \u00b1 3.0%, respectively), and occipital lobe (\u22120.3% \u00b1 1.8% vs. \u22122.7% \u00b1 3.2%, respectively). A trend toward reduced atrophy also was observed in the frontal lobe, hippocampus, caudate nucleus, midbrain, and brainstem. In patients with PSP, tideglusib reduced the progression of atrophy in the whole brain, particularly in the parietal and occipital lobes. \u00a9 2014 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.25815","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T23:57:13Z","timestamp":1391212633000},"page":"479-487","source":"Crossref","is-referenced-by-count":145,"title":["Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial"],"prefix":"10.1002","volume":"29","author":[{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"first","affiliation":[{"name":"Department of Neurology Philipps Universit\u00e4t Marburg Germany"},{"name":"Department of Neurology Technische Universit\u00e4t M\u00fcnchen Munich Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010J\u00fcrgen","family":"Huppertz","sequence":"additional","affiliation":[{"name":"Swiss Epilepsy Centre Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wagenpfeil","sequence":"additional","affiliation":[{"name":"Institute for Medical Biometry, Epidemiology and Medical Informatics (IMBEI) Universit\u00e4tsklinikum des Saarlandes Homburg\/Saar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Clinical Operations Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincente","family":"Belloch","sequence":"additional","affiliation":[{"name":"Scientific Department Exploraciones Radiol\u00f3gicas Especiales (ERESA) Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Le\u00f3n","sequence":"additional","affiliation":[{"name":"Clinical Operations Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodoro","family":"del Ser","sequence":"additional","affiliation":[{"name":"Medical Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the TAUROS MRI Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/505607"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205052772713"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.05226.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq115"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-002-0587-8"},{"key":"e_1_2_9_7_1","first-page":"533","article-title":"Glycogen synthase kinase\u20103 (GSK\u20103) inhibitors reach the clinic","volume":"11","author":"Medina M","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm011020u"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.306472"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.05.025"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_2_9_12_1","first-page":"A326","article-title":"The Medical Advisory Board of the Society for Progressive Supranuclear Palsy. A clinical rating scale and staging system for progressive supranuclear palsy","volume":"48","author":"Golbe LI","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.6.1318"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"e_1_2_9_15_1","volume-title":"Dementia Rating Scale\u20102 Professional Manual","author":"Jurica PJ","year":"2001"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621"},{"key":"e_1_2_9_17_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_9_18_1","first-page":"152","volume-title":"Third Symposium on Parkinson's Disease","author":"Schwab RS","year":"1969"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.10.066"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.21304"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1109\/42.640753"},{"key":"e_1_2_9_22_1","first-page":"1165","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini Y","year":"2000","journal-title":"Ann Stat"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3181aba588"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165960.04422.D0"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2453061703"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e55d0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.10.013"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm104"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25815","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:26:09Z","timestamp":1760952369000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/mds.25815"],"URL":"https:\/\/doi.org\/10.1002\/mds.25815","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}